AR078504A1 - Compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene - Google Patents

Compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene

Info

Publication number
AR078504A1
AR078504A1 ARP100103609A ARP100103609A AR078504A1 AR 078504 A1 AR078504 A1 AR 078504A1 AR P100103609 A ARP100103609 A AR P100103609A AR P100103609 A ARP100103609 A AR P100103609A AR 078504 A1 AR078504 A1 AR 078504A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
denotes
integer
alkyl
Prior art date
Application number
ARP100103609A
Other languages
English (en)
Inventor
Vasily Artemov
Heui Sul Park
Ki Chul Koo
Cheol Kyu Jung
Eun Sil Choi
Tae Hun Kim
Hyun Jung Park
Wan Su Park
Jeong-Uk Song
Geun Tae Kim
Sung-Pil Choi
Deok Seong Park
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43857261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078504(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of AR078504A1 publication Critical patent/AR078504A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a compuestos que son eficaces como un inhibidor para la xantina-oxidasa, a un proceso para preparar los mismos y a una composicion farmacéutica que comprende una cantidad terapéuticamente efectiva de los mismos. Reivindicacion 1: Compuestos de la siguiente formula (1): en la formula (1) anterior, A se selecciona entre los siguientes sustituyentes A-i, A-ii, A-iii, A-iv, A-v, A-vi, A-vii y A-viii: (A-i a A-iii) en la cual J representa hidrogeno, halogeno, o halogeno-alquilo C1-6 sustituido o insustituido, X representa O o S, Z representa C o N, E representa hidrogeno, halogeno, ciano, nitro, alquilo C1-6 sustituido o insustituido, o alcoxi C1-6 sustituido o insustituido, D representa hidrogeno, halogeno, ciano, nitro, halogeno-alquilo C1-6 sustituido o insustituido, -CHO, o -CH=N-OH, Q se selecciona entre los sustituyentes: hidrogeno; alquilo sustituido o insustituido, saturado o insaturado y de cadena recta, ramificada o cíclica; (2) (donde W representa O o S, R7 representa hidrogeno, o alquilo inferior sustituido o insustituido, y n denota un numero entero de 0 3); (3) (donde W representa O o S, R8 y R9, cada uno de ellos, representa hidrogeno o alquilo inferior, y m denota un numero entero de 1 3); (4) (donde R8 y R9, cada uno de ellos, representa hidrogeno o alquilo inferior, y m denota un numero entero de 1 3); (5) (donde R10 y R11, cada uno de ellos, representa hidrogeno, halogeno, alcoxi inferior o alquilo inferior, y m denota un numero entero de 1 3); (6) (donde R12 representa alquilo inferior sustituido o insustituido o un grupo aromático, y n denota un numero entero de 0 3); (7) (donde R13 y R14, cada uno de ellos, representa alquilo inferior sustituido o insustituido o, junto con el grupo N al cual están unidos, pueden formar un heterociclo de 3 a 7 miembros, y n denota un numero entero de 0 3); (8) (donde R15 representa alquilo inferior sustituido o insustituido, y m denota un numero entero de 1 3); (9) (donde m denota un numero entero de 1 3); (donde R15 representa alquilo inferior sustituido o insustituido, y m denota un numero entero de 1 3); Y representa hidrogeno, halogeno, alquilo sustituido o insustituido, saturado o insaturado y de cadena recta, ramificada o cíclica, alcoxi C1-6 sustituido o insustituido, o un grupo aromático o heteroaromático sustituido o insustituido, y G representa hidrogeno o representa alquilo sustituido o insustituido, saturado o insaturado y de cadena recta, ramificada o cíclica, sales farmacéuticamente aceptables o isomeros de los mismos.
ARP100103609A 2009-10-07 2010-10-05 Compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene AR078504A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20090095363 2009-10-07

Publications (1)

Publication Number Publication Date
AR078504A1 true AR078504A1 (es) 2011-11-09

Family

ID=43857261

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103609A AR078504A1 (es) 2009-10-07 2010-10-05 Compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene

Country Status (27)

Country Link
US (1) US8729273B2 (es)
EP (1) EP2467378B1 (es)
JP (1) JP5702392B2 (es)
KR (1) KR101751325B1 (es)
CN (1) CN102574839B (es)
AP (1) AP3346A (es)
AR (1) AR078504A1 (es)
AU (1) AU2010304091B2 (es)
BR (1) BR112012007828B8 (es)
CA (1) CA2774133C (es)
CL (1) CL2012000738A1 (es)
CO (1) CO6430501A2 (es)
EA (1) EA021025B1 (es)
EC (1) ECSP12011793A (es)
ES (1) ES2599829T3 (es)
HK (1) HK1170224A1 (es)
IL (1) IL218669A (es)
MA (1) MA33880B1 (es)
MX (1) MX2012003782A (es)
MY (1) MY162813A (es)
PE (1) PE20121088A1 (es)
SG (1) SG179186A1 (es)
TR (1) TR201203989T1 (es)
TW (1) TWI423962B (es)
UA (1) UA110197C2 (es)
WO (1) WO2011043568A2 (es)
ZA (1) ZA201202544B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
EP3243515B1 (en) * 2011-08-30 2019-10-16 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MY176149A (en) 2013-03-29 2020-07-24 Teijin Pharma Ltd Pyrazole derivative
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
CN104774172B (zh) * 2015-04-08 2017-03-22 河南师范大学 一种3‑氰基吲哚类化合物的合成方法
AU2016316278B2 (en) * 2015-09-02 2020-06-04 Sunshine Lake Pharma Co., Ltd. Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
CN110612286A (zh) * 2017-02-28 2019-12-24 广东东阳光药业有限公司 氰基取代的稠合双环衍生物及其制备方法和用途
IL276783B2 (en) * 2018-06-01 2023-12-01 Autophagysciences Inc The composition and pharmaceutical compound containing it
CN111072647B (zh) * 2019-12-11 2021-02-26 沈阳药科大学 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
TW202336015A (zh) * 2020-11-04 2023-09-16 南韓商Ｌｇ化學股份有限公司 唑－４－羧酸結晶之製備方法及包含彼之醫藥組成物
AU2021392532A1 (en) 2020-12-01 2023-06-29 Lg Chem, Ltd. Oral formulation comprising 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid and method for preparing same
CN116528852A (zh) 2020-12-01 2023-08-01 株式会社Lg 化学 含有1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的稳定的口服制剂
CN112920170B (zh) * 2021-01-29 2023-06-20 中国医科大学 N-（吲哚-5-基）芳香杂环酰胺类化合物及其制备方法和用途
MX2023011500A (es) * 2021-04-16 2023-10-04 Lg Chemical Ltd Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico.
CN117242062A (zh) * 2021-04-27 2023-12-15 株式会社Lg化学 用于合成黄嘌呤氧化酶抑制剂的中间体的制备方法
CN117203200A (zh) * 2021-04-27 2023-12-08 株式会社Lg化学 黄嘌呤氧化酶抑制剂的制备方法
WO2022231263A1 (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
KR20240005050A (ko) * 2021-04-29 2024-01-11 쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 크산틴 옥시다아제 억제제
CN117412746A (zh) * 2021-06-15 2024-01-16 株式会社Lg化学 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的药物组合物
AR126164A1 (es) 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
TWI822151B (zh) 2021-07-02 2023-11-11 南韓商Ｌｇ化學股份有限公司 製備黃嘌呤氧化酶抑制劑的方法
KR20230006408A (ko) 2021-07-02 2023-01-10 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
WO2023208103A1 (zh) * 2022-04-27 2023-11-02 江苏新元素医药科技有限公司 可用于痛风的化合物
CN116715633A (zh) * 2022-04-27 2023-09-08 江苏新元素医药科技有限公司 可用于降尿酸的化合物
CN116283946B (zh) * 2023-03-27 2024-05-07 武汉工程大学 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU218942B (hu) 1990-11-30 2001-01-29 Teijin Ltd. 2-Fenil-tiazol-származékok, az ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek előállítására
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
AU2001270260A1 (en) * 2000-06-30 2002-01-14 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
JP2004502768A (ja) * 2000-07-10 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー 置換インドールオキソアセチックピペラジン誘導体の組成物と抗ウイルス活性
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
WO2004014354A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
KR20080035594A (ko) * 2005-07-01 2008-04-23 닛뽕 케미파 가부시키가이샤 크산틴옥시다아제 저해제
RU2008118156A (ru) 2005-10-07 2009-11-20 Астеллас Фарма Инк. (Jp) Производное триарилкарбоновой кислоты
EP2044055A4 (en) * 2006-07-21 2011-03-23 Takeda Pharmaceutical amide compounds
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP2008179621A (ja) * 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
WO2008126770A1 (ja) 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
CN101679251B (zh) * 2007-04-11 2013-10-02 橘生药品工业株式会社 (氮杂)吲哚衍生物及其医药用途
JP5378988B2 (ja) 2007-04-11 2013-12-25 キッセイ薬品工業株式会社 ５員環へテロ環誘導体及びその医薬用途
US20110201815A1 (en) * 2008-10-15 2011-08-18 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative and use thereof for medical purposes
CA2740766C (en) 2008-10-16 2016-02-02 Automatic Bar Controls, Inc. Apparatus and method and turntable for on-demand distributing of a food product
JP5529876B2 (ja) * 2008-10-17 2014-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−１３阻害剤として有用なヘテロアリール置換インドール化合物
CN102574788A (zh) * 2009-09-24 2012-07-11 弗·哈夫曼-拉罗切有限公司 作为crac调节剂的吲哚衍生物

Also Published As

Publication number Publication date
CA2774133A1 (en) 2011-04-14
US8729273B2 (en) 2014-05-20
CN102574839B (zh) 2015-11-25
EA201270520A1 (ru) 2012-10-30
BR112012007828B8 (pt) 2021-05-25
AU2010304091B2 (en) 2016-06-09
ECSP12011793A (es) 2012-05-30
PE20121088A1 (es) 2012-08-17
KR20110037883A (ko) 2011-04-13
ES2599829T3 (es) 2017-02-03
WO2011043568A3 (en) 2011-09-29
KR101751325B1 (ko) 2017-06-27
HK1170224A1 (zh) 2013-02-22
WO2011043568A2 (en) 2011-04-14
SG179186A1 (en) 2012-05-30
CL2012000738A1 (es) 2012-09-14
IL218669A (en) 2016-08-31
UA110197C2 (ru) 2015-12-10
AP3346A (en) 2015-07-31
TWI423962B (zh) 2014-01-21
EA021025B1 (ru) 2015-03-31
ZA201202544B (en) 2012-12-29
CN102574839A (zh) 2012-07-11
AU2010304091A1 (en) 2012-04-19
TR201203989T1 (tr) 2012-09-21
JP2013507355A (ja) 2013-03-04
MY162813A (en) 2017-07-31
IL218669A0 (en) 2012-05-31
MA33880B1 (fr) 2013-01-02
EP2467378A4 (en) 2013-04-24
EP2467378B1 (en) 2016-07-27
AP2012006191A0 (en) 2012-04-30
JP5702392B2 (ja) 2015-04-15
US20120184582A1 (en) 2012-07-19
TW201118077A (en) 2011-06-01
CO6430501A2 (es) 2012-04-30
MX2012003782A (es) 2012-08-31
BR112012007828B1 (pt) 2021-01-12
EP2467378A2 (en) 2012-06-27
BR112012007828A2 (pt) 2016-03-08
CA2774133C (en) 2019-06-25

Similar Documents

Publication Publication Date Title
AR078504A1 (es) Compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PE20171057A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
PE20191744A1 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
ECSP12012103A (es) Inhibidores de virus flaviviridae.
AR064561A1 (es) Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
PA8815201A1 (es) Compuestos heterociclicos
PE20141124A1 (es) Derivados de imidazol fusionados, utiles como inhibidores de ido
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
CO7240410A2 (es) Inhibidores macrocíclicos de virus flaviviridae
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR094790A1 (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
MA32570B1 (fr) NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
BR112013004662B8 (pt) Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica

Legal Events

Date Code Title Description
FG Grant, registration